NextCure, Inc.
$11.7
▲
1.8%
2026-04-21 08:33:02
www.nextcure.com
NMS: NXTC
Explore NextCure, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$41.66 M
Current Price
$11.7
52W High / Low
$15.74 / $3.85
Stock P/E
—
Book Value
$9.97
Dividend Yield
—
ROCE
-145.43%
ROE
-1.11%
Face Value
—
EPS
$-19.65
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
40
Beta
1.58
Debt / Equity
14.75
Current Ratio
4.14
Quick Ratio
4.14
Forward P/E
-1.84
Price / Sales
—
Enterprise Value
$4.78 M
EV / EBITDA
-0.09
EV / Revenue
—
Rating
None
Target Price
$17.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Septerna, Inc. | $26.86 | — | $1.17 B | — | -15.87% | -12.19% | $32.63 / $5.73 | $8.52 |
| 2. | XOMA Royalty Corporation | $40 | 14.61 | $463.38 M | 1.18% | 4.79% | 34.12% | $40.74 / $20.59 | $7.07 |
| 3. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 4. | ABVC BioPharma, Inc. | $1.3 | — | $33.58 M | — | -48% | -1.19% | $5.48 / $0.81 | $0.46 |
| 5. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 6. | Equillium, Inc. | $2.01 | — | $127.09 M | — | -81.63% | -94% | $2.7 / $0.27 | $0.47 |
| 7. | Prelude Therapeutics Incorporated | $4.51 | — | $279.73 M | — | -118.39% | -99.45% | $5.54 / $0.72 | $0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.76 M | -8.95 M | -27.29 M | -11.62 M | -12.46 M | — |
| Net Profit | -9.44 M | -8.62 M | -26.81 M | -10.98 M | -11.6 M | — |
| EPS in Rs | -2.65 | -2.42 | -7.53 | -3.08 | -3.26 | -4.95 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -57.62 M | -57.21 M | -67.64 M | -75.91 M |
| Net Profit | -55.84 M | -55.65 M | -62.72 M | -74.73 M |
| EPS in Rs | -15.68 | -15.63 | -17.62 | -20.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 50.18 M | 80.86 M | 128.04 M | 184.16 M |
| Total Liabilities | 15.24 M | 15.39 M | 13.62 M | 16.63 M |
| Equity | 34.94 M | 65.47 M | 114.42 M | 167.53 M |
| Current Assets | 43.75 M | 71.81 M | 112.72 M | 163.98 M |
| Current Liabilities | 10.57 M | 9.57 M | 6.88 M | 9.13 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -49.61 M | -40.8 M | -52.97 M | -53.89 M |
| Investing CF | 25.56 M | 55.31 M | 39.27 M | 67.98 M |
| Financing CF | 22.31 M | 0.14 M | 0.15 M | 0.2 M |
| Free CF | -49.61 M | -41.28 M | -53.79 M | -56 M |
| Capex | — | -0.47 M | -0.82 M | -2.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -0.34% | 11.27% | 16.07% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-14 | 1:0.0833333 |